Neonc Technologies CFO sells $16,809 in company stock

Keithly Garnett, the CFO of NEONC Technologies Holdings, Inc., sold 5,000 shares of the company's common stock on September 15, 2026. The transaction, conducted per a Rule 10b5-1 trading plan adopted on June 16, 2026, involved selling the shares at $3.3618 per share, generating a total of $16,809. This sale occurred as NEONC Technologies' stock price was trading at $3.26, marking a 73% decline over the past year.

Despite the price drop, InvestingPro analysis indicates the stock is undervalued at its current level, with 10 additional ProTips available to subscribers. Following the sale, Garnett still holds 237,357 shares of NEONC Technologies Holdings common stock, including shares held by certain family members, for which he disclaims ownership except for any financial interest.

Additionally, he indirectly owns 44,053 shares of HCWG LLC through The Hilkiah Group LLC, of which he is the sole member. NEONC Technologies recently announced positive results from its Phase 2a study of intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, which met its primary endpoint and received FDA feedback on manufacturing requirements for NEO212.

The company also received Investigational New Drug approval from Abu Dhabi's Department of Health for NEO100, covering multiple study protocols in adults and children with progressive or recurrent gliomas. These developments highlight ongoing advancements in NEONC's clinical trials and regulatory engagements.